RECORDATI GROUP

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 4 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

3 drugs in development

Phase 22

Preclinical1

By Therapeutic Area

top 1

Metabolic & Endocrine

267%

R&D Momentum

41/100

Pipeline Velocity

11/100

Trial Completion Rate

76/100

Pipeline Concentration

56/100

Pipeline Freshness

51/100

Strategic Signals

↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Nov 3, 2026

Recruiting

A Double-blind, Randomised, 30-week Placebo-controlled Phase IV Study to Assess the Efficacy and Safety of Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

Oct 27, 2026

Active, not recruiting

A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta

Earlier

Oct 7, 2026TrialEfficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients

Sep 18, 2026TrialA Double-blind Randomized Placebo-controlled Dose-finding Phase II Study to Assess the Efficacy and Safety of Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Dec 1, 2025TrialStudy in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule

Jul 11, 2024FDASignifor — SIGNIFOR

Jul 11, 2024FDASignifor — SIGNIFOR LAR KIT

Jan 16, 2023TrialOsilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

4 more events

Jun 30, 2022TrialAn Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

Jun 13, 2022TrialNon-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Feb 21, 2022TrialReal-life Observational Study of Cancer Pain Management With Methadone

Apr 28, 2021TrialPharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

9 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Valchlor5 patentsMar 7, 2026 IsturisaAug 23, 2026 Signifor2 patentsOct 25, 2026 SigniforMay 23, 2028 IsturisaMar 27, 2029 ValchlorJul 8, 2029 Isturisa2 patentsJan 13, 2031 NeoprofenMar 2, 2032

1 more

Isturisa2 patentsJul 6, 2035

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

LCI699Phase 2

Hypoglycemia

SigniforPhase 2

Unknown / Other

Efficacy

CarbagluPreclinical

Regulatory

Regulatory Timeline

20121 event

FDADec 14

Signifor — SIGNIFOR

Application NDA200677 (NDA)

20133 events

FDAAug 23

Valchlor — VALCHLOR

Application NDA202317 (NDA)

FDAAug 23

Valchlor — VALCHLOR

Application NDA202317 (NDA)

FDAFeb 13

Signifor — SIGNIFOR

Application NDA200677

20141 event

FDAApr 23

Sylvant — SYLVANT

Application BLA125496 (BLA)

20152 events

FDAJul 8

Signifor — SIGNIFOR LAR KIT

Application NDA203255

FDAMar 17

Signifor — SIGNIFOR

Application NDA200677

20184 events

FDAJun 29

Signifor — SIGNIFOR LAR KIT

Application NDA203255 (NDA)

FDAJun 29

Signifor — SIGNIFOR LAR KIT

Application NDA203255

FDAMar 9

Signifor — SIGNIFOR

Application NDA200677

FDAMar 9

Signifor — SIGNIFOR LAR KIT

Application NDA203255

20194 events

FDAApr 11

Signifor — SIGNIFOR LAR KIT

Application NDA203255

FDAApr 11

Signifor — SIGNIFOR

Application NDA200677

FDAJan 29

Signifor — SIGNIFOR LAR KIT

Application NDA203255

FDAJan 29

Signifor — SIGNIFOR

Application NDA200677

20203 events

FDAJul 9

Signifor — SIGNIFOR LAR KIT

Application NDA203255

FDAMar 6

Isturisa — ISTURISA

Application NDA212801 (NDA)

FDAJan 15

Signifor — SIGNIFOR

Application NDA200677

20242 events

FDAJul 11

Signifor — SIGNIFOR

Application NDA200677

FDAJul 11

Signifor — SIGNIFOR LAR KIT

Application NDA203255

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)